MAPT and memory impairment: In a similar setting with our study, SCR1693, a synthesized hybrid compound composed of an acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) was previously found to improve memory impairments [53,54], cell death and hippocampal neuron loss [55], inhibited Aβ production and induced tau dephosphorylation [35].